e, nifedipine, nicardipine) and medicines used to correct heart
rhythm (e.g., bepridil, systemic lidocaine, quinidine), antifungals, (e.g.,
ketoconazole, itraconazole), morphine-like medicines (e.g., methadone)
anticonvulsants (e.g., carbamazepine, phenytoin, phenobarbital), warfarin,
certain antibiotics (i.e., rifabutin, clarithromycin), certain
antidepressants (e.g. trazodone) and voriconazole. Kaletra may interact
with erectile dysfunction agents (e.g., sildenafil or tadalafil). Lower
doses of these medicines should be prescribed in patients taking Kaletra.
Kaletra may interact with digoxin (heart medicine); monitoring by a
physician is recommended.
Taking Kaletra with certain medicines can cause increased levels of
these other medicines in the body. This could increase or prolong their
effects and/or adverse reactions, which may result in serious or
life-threatening problems. Because of this, patients must tell their doctor
about all medicines they are taking or planning to take, including those
medicines that can be bought without a prescription and herbal
Patients using an oral contraceptive or using a patch contraceptive to
prevent pregnancy should use an additional or alternative type of
contraception since Kaletra may reduce the effectiveness of these products.
Pregnant or nursing mothers should not take Kaletra unless specifically
directed by their doctor.
Kaletra oral solution contains 42 percent alcohol. While taking Kaletra
oral solution, patients should not take any medicines that may cause a
reaction with alcohol such as disulfiram.
It is important that Kaletra oral solution is taken with food. Kaletra
tablets may be taken with or without food.
Cases of pancreatitis have been reported in patients taking Kaletra.
Liver problems, which can be fatal, have also been reported. Patients
should tell their doctor if they have had liver disease such as chronic
hepatitis B or C as they are at increased risPage: 1 2 3 4 5 6 7 8 Related medicine news :1
. Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients2
. Ugandan Children Are Among the First to Receive Abbotts Lower-Strength Aluvia (lopinavir/ritonavir) Tablet3
. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis4
. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet5
. Actavis Launches Carvedilol Tablets in the U.S.6
. Mylan Announces Final FDA Approval for Carvedilol Tablets7
. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market8
. Actavis Launches Amlodipine Tablets in the U.S.9
. Tablet is better all round for cancer patients10
. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg11
. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline